The effect of hypertension and hypercholesterolemia screening with subsequent intervention letter on the use of blood pressure and lipid lowering drugs

British Journal of Clinical Pharmacology

Volumn 57, Issue 3, 2004, Pages 328-336

  Atthobari, Jarir ^a   Monster, Taco B M ^a   De Jong, Paul E ^a   De Jong Van Den Berg, Lolkje T W ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

Blood pressure lowering drug; General practitioner; Hyperlipidemia; Hypertension; Incidence; Intervention; Letter; Lipid lowering drug; Patient; Population screening; Predictor variable; Prevalence

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT;

ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DATA BASE; DRUG USE; EVALUATION; GENERAL PRACTITIONER; HEALTH SURVEY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTENSION; MASS SCREENING; NETHERLANDS; OUTCOMES RESEARCH; PREDICTION; PRESCRIPTION; PRIORITY JOURNAL;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; ANTILIPEMIC AGENTS; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; HYPERTENSION; MALE; MASS SCREENING; MEDICAL RECORDS; MIDDLE AGED; PROGRAM EVALUATION; REFERRAL AND CONSULTATION; RISK FACTORS;

EID: 1542359662     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2003.02011.x     Document Type: Article

References (32)

1. US Preventive Task Force. Screening of Hypertension in Guide to Clinical Prevention, 2nd edn. Washington DC 1989.
2. MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J, Abbott R, Godwin J, Dyer AJ, Stamler J. Blood pressure, stroke and coronary heart disease. Part 1, Prolonged differences in blood pressure, prospective observational studies corrected for the regression dilution bias. Lancet, 1990; 335: 765-74.
3. Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KA, Godwin J, Qizilbash N, Taylor JO, Hennekens CH. Blood pressure, stroke and coronary heart disease. Part 2, short term reductions in blood presure: overview of randomized drug trials in their epidemiological context. Lancet, 1990; 335: 827-38.
4. MacMahon S. Blood pressure and the risk of cardiovascular disease. N Eng J Med, 2000; 342 (1): 49-52.
5. Green R, Kwok S, Durrington PN. Preventing cardiovascular disease in hypertension: effects of lowering blood pressure and cholesterol. QJM, 2002; 95: 821-6.
6. Bucher HC, Griffith LE, Guyatt GH. Effect of HMG CoA reductase inhibitors on stroke. A Meta analysis randomized controlled trial. Ann Intern. Med, 1998; 128 (2): 89-95.
7. Belsey B. Lipid lowering in coronary heart disease. Evidence Based Med Prac, 1998; 1: 1-8.
8. Mulrow PJ. Detection and control of hypertension in the population: United States experience. Am J Hypertens, 1998; 11: 744-6.
9. Wolf HK, Tuomilehto J, Kuulasmaa K, Domarkiene S, Cepaitis Z, Molarius A, Sans S, Dobson A, Keil U, Rywik S for the WHO MONICA Project. Blood pressure levels in the 41 populations of the WHO MONICA project. J Hum Hypertens, 1997; 11: 733-42.
10. Gill PS, Makela M, Vermeulen KM, Freemantle N, Ryan G, Bond C, Thorsen T, Haaijer Ruskamp FM. Changing doctor prescribing behaviour. Pharm Word Sci, 1999; 21: 158-67.
11. Le Grand A, Hogerzeil HV, Haaijer-Ruskamp FM. Intervention researches in rational use of drugs: a review. Health Policy Plan, 1999; 14: 89-102.
12. World Health Organization Depart. Communicable Dis Surveill. and Response. Intervention and Strategies to Improve the Use of Antimicrobials in Developing Countries: a Review. WHO. Geneva, 2001.
13. Collins TM, Mott DA, Bigelow WE, Zimmerman DR, A. controlled letter intervention to change prescribing behaviour; results of dual targeted approach. Health Serv Res, October 1997; 32: 471-89.
14. Rascati KL, Okano GJ, Burch C. Evaluation of physician intervention letters. Med Care, 1996 August; 34: 760-6.
15. Mott DA, Collins TM. Comparison of targetting a DUR letter intervention at pharmacists separate from and in addition to physicians. J Am Pharm Assoc May. - June 1998; 38: 325-32.
16. Wrobel M, Chatterji P. Do. Medicaid Retrospective Drug Utilization Review Letter Interventions Improve the Quality of Prescription Drug Therapy? 15th Annual. Meeting Association for Health Services Research,.: Washington.
17. Pinto-Sietsma S-J, Janssen WMT, Hillege HL, Navis G, de Zeeuw D, de Jong PE. Urinary albumin excretion is associated with renal functional abnormalities in a nondiabetic population. J Am Soc Nephrol 2000, June 21-23, 1998; 11: 1882-8.
18. Monster TBM, Janssen WNT, de Jong PE, de Jong-van den Berg LTW. The impact of antihypertensive drug groups on urinary albumin excretion in a non-diabetic population. Br J Clin Pharmacol, 2002; 53: 31-6.
19. Tobi H, van den Berg PB, de Jong-van den Berg LTW. The Interaction Database: synergy of science and practice in pharmacy. In: Medical Data Analysis. Lecture Notes in Computer Sciences (1933), Brause, RW, Hanisch, E, eds. Springer, Frankfurt, Germany., 2000: 206-11.
20. Seidell JC. Verworven Eigenschappen Bloeddruk. In: Maas IAM, Gijsen R, Lobbezoo IE, Poos MJJC, Eindredactie. Volksgezondheid Toekomst Verkenning 1997. Bilthoven: Rijkinstituut Voor Volksgezondheid En Milieu. 1997: 640-6.
21. Klungel OH, de Boer A, Paes AHP, Seidell JC, Nagelkerke NJD, Bakker A. Undertreatment of hypertension in a population-based study in the Netherlands. J Hypertens, 1998; 16: 1371-8.
22. Mantel-Teeuwisse AK, Klungel OH, Verschuren WMM, Porsius AJ, de Boer A. Time trends in lipid lowering drug use in The Netherlands. Has the backlog of candidates for treatment been eliminated? Br J Clin Pharm, 2002; 53: 379-85.
23. Mantel-Teeuwisse AK, Klungel OH, Verschuren WMM, Porsius AJ, de Boer A. Myopathy due to statin/fibrate use in the Netherlands. Ann Pharmacother, 2002; 36: 1957-60.
24. Feder G, Griffiths C, Eldridge S, Spence M. Effect of postal prompts to patients and general practitioners on quality of primary care after a coronary events (POST): randomized controlled trial. BMJ, 1999; 318: 1522-6.
25. Edward R, Murphy P. Are postal prompts really ineffective?: letter. BMJ, 1999; 319: 711.
26. Gupta K, Gupta S. Valhalla. Undertreatment of hypertension: a dozen reasons. Arch Intern Med, 2002; 162: 2246-7.
27. The Guideline Subcommittee World Health organization and International Society of Hypertension (WHO-ISH) Mild Hypertension Liaison Committee. World Health organization-International Society of Hypertension of hypertension guideline for the management of hypertension. J Hypertens 1999, 1999; 17: 151-83.
28. Unwin N, Thomson R, O'Byrne AM, Laker M, Armstrong H. Implications of applying widely accepted cholesterol screening and management guidelines to a british adult population, cross sectional study of cardiovascular disease and risk factors. BMJ, 1998; 317: 1125-30.
29. Ramsay LE, Williams B, Johnston GD, MacGregor GA, Poston L, Potter JF, Poulter NR, Russell G. for the British Hypertension Society, Guidelines for management of hypertension, report of the third Working Party of the British Hypertension Society. J Hum Hypert, 1999; 13: 569-92.
30. Feldman RD, Campbell N, Larochelle P, Bolli P, Burgess ED, Carruthers SG, Floras JS, Haynes RB, Honos G, Leenen FHH, Leiter LA, Logan AG, Myers MG, Spence JD, Zarnke KB. for the Task Force for the Development of the. Canadian Recommendations for the Management of Hypertension.(Suppl)to CMAJ 1999; 161 (12 Suppl): S1-17.
31. Frijling BD, Spies TH, Lobo CM, Hulscher MEJL, van Drenth BB, Braspenning JCC et al. Blood pressure control in treated hypertensive patients: clinical performance of general practitioners. Br J General Prac, 2001; 51: 9-14.
32. Tijmstra T, Spijkers EW, Broer J, Janssen WMT, de Jong PE. Psychosocial and consequences of a screening for microalbuminuria and some other risk factors. Ned Tijdschr Geneeskd, 2000; 144 (51): 2460-4.